Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b)
Effective as of May 25, 2022, Daniel Soland resigned from his position on the
Board of Directors (the "Board") of KalVista Pharmaceuticals, Inc. (the
"Company") and all committees thereof. Mr. Soland's resignation is not the
result of any disagreement with the Company on any matter relating to the
Company's operations, policies or practices.
(d)
On May 26, 2022 upon the recommendation of the Nominating and Governance
Committee of the Board, the Board approved the appointment of Patrick Treanor
("Mr. Treanor") to the Board effective immediately, to serve until his successor
is duly elected and qualified, or until his death, resignation or removal. Mr.
Treanor will serve as a Class II Director whose term will expire at the
Company's 2024 Annual Meeting of Stockholders.
There are no arrangements or understandings between Mr. Treanor and any other
persons pursuant to which Mr. Treanor was named as a director. Mr. Treanor is
not a party to any transaction required to be disclosed pursuant to Item 404(a)
of Regulation S-K. Additionally, the Board has determined that Mr. Treanor
satisfies the independence requirements of the NASDAQ Stock Market listing rules
and the Securities and Exchange Commission.
Mr. Treanor's compensation shall be consistent with the Company's current policy
for incoming non-employee directors, which provides for (i) an initial award
upon such individual's first appointment to the Board, consisting of options to
purchase 17,000 shares of the Company's common stock (ii) an annual retainer of
$42,500 paid in cash and (iii) an annual award to be granted commencing on the
date of the first annual meeting of stockholders after Mr. Treanor has been
serving as a director for one year, consisting of options to purchase 10,000
shares of the Company's common stock.
In connection with his appointment to the Board, Mr. Treanor will execute the
Company's standard form of indemnification agreement for directors.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
KALVISTA PHARMACEUTICALS, INC. 
